Sign In
Buy PTIX
$0.410
+0 (+0%)
At Close: Jun 22, 2026
NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuro
NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-rel
Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX)
01:09am, Tuesday, 14'th Apr 2026
Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report) and Atrinsic (NASDAQ: PTIX - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two com
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
08:00am, Tuesday, 17'th Mar 2026
Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW YO
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
08:00am, Tuesday, 10'th Mar 2026
Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeut
Atrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy?
02:51am, Wednesday, 04'th Mar 2026
Atrinsic Inc. (NASDAQ: PTIX - Get Free Report)'s stock price was up 10.9% during trading on Tuesday. The company traded as high as $0.50 and last traded at $0.50. Approximately 2,974 shares traded han
Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX)
02:10am, Monday, 19'th Jan 2026
Atrinsic (NASDAQ: PTIX - Get Free Report) and Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) are both medical companies, but which is the better business? We will contrast the two compani
Results from Phase 1 Multiple-Dose Study of PT00114
08:46am, Tuesday, 09'th Dec 2025
Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protage
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
03:45am, Thursday, 27'th Nov 2025
NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qual
Atrinsic (NASDAQ:PTIX) Trading Up 2.5% – Time to Buy?
02:34am, Saturday, 22'nd Nov 2025
Atrinsic Inc. (NASDAQ: PTIX - Get Free Report) shares were up 2.5% on Friday. The stock traded as high as $2.15 and last traded at $2.07. Approximately 56,058 shares were traded during trading, a decl
Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
08:22am, Thursday, 13'th Nov 2025
NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
05:25pm, Friday, 22'nd Aug 2025
Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing nove
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
08:12am, Thursday, 21'st Aug 2025
Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceuti
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
08:30am, Wednesday, 30'th Jul 2025
NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Of
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
08:30am, Wednesday, 30'th Jul 2025
NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office
